Millipore Sigma Vibrant Logo

420116 JNK Inhibitor I, (L)-Form, Cell-Permeable - Calbiochem

JNK Inhibitor I, (L)-Form, Cell-Permeable peptide with a C-terminal sequence from the JNK-binding domain and an N-terminal peptide with HIV-TAT48-57 sequence. Blocks c-jun activation (IC50 ~ 1 µM).

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: (L)-JNKI1, (L)-HIV-TAT₄₈₋₅₇-PP-JBD₂₀, H-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT-NH₂, c-Jun NH₂-terminal kinase, SAPK Inhibitor I

Primary Target: JNK
View Products on Sigmaaldrich.com
420116
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

Empirical Formula
C₁₆₈H₂₉₃N₆₇O₄₂

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
420116-1MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 1 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA cell-permeable, biologically active peptide consisting of a carboxyl terminal sequence derived from the JNK-binding domain (JBD) and an amino terminal peptide containing the HIV-TAT48-57 sequence. Blocks c-Jun NH2-terminal kinase (JNK) signaling by preventing the activation of the transcription factor c-jun (IC50 ~ 1 µM). This effect appears to be due to inhibition of phosphorylation of the activation domains of JNK. Contains the minimal 20-amino acid inhibitory domain of islet-brain (IB) that is shown to be critical for interaction with JNK linked to the 10-amino acid HIV-TAT48-57 sequence as a carrier peptide and two proline residues as spacer. Inhibits IL-1β-induced c-jun and c-fos expression in insulin secreting βTC-3 cells and offers protection against apoptosis. Does not affect insulin secretion and has no effect on either ERK 1/2 or p38 activities.
      Catalogue Number420116
      Brand Family Calbiochem®
      Synonyms(L)-JNKI1, (L)-HIV-TAT₄₈₋₅₇-PP-JBD₂₀, H-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT-NH₂, c-Jun NH₂-terminal kinase, SAPK Inhibitor I
      References
      ReferencesBarr, R.K., et al. 2002. J. Biol. Chem. 277, 10987.
      Bonny, C., et al. 2001. Diabetes 50, 77.
      Product Information
      ATP CompetitiveN
      DeclarationSold under license of U.S. Patents 6,043,083 and 6,410,693.
      FormWhite lyophilized solid
      FormulationSupplied as a trifluoroacetate salt.
      Hill FormulaC₁₆₈H₂₉₃N₆₇O₄₂
      Chemical formulaC₁₆₈H₂₉₃N₆₇O₄₂
      Hygroscopic Hygroscopic
      ReversibleN
      Quality LevelMQ100
      Applications
      ApplicationJNK Inhibitor I, (L)-Form, Cell-Permeable peptide with a C-terminal sequence from the JNK-binding domain and an N-terminal peptide with HIV-TAT48-57 sequence. Blocks c-jun activation (IC50 ~ 1 µM).
      Biological Information
      Primary TargetJNK
      Primary Target IC<sub>50</sub>1 µM
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableY
      Peptide SequenceH-Gly-Arg-Lys-Lys-Arg-Agr-Gln-Arg-Arg-Arg-Pro-Pro-Arg-Pro-Lys-Arg-Pro-Thr-Thr-Leu-Asn-Leu-Phe-Pro-Gln-Val-Pro-Arg-Ser-Gln-Asp-Thr-NH₂
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      420116-1MG 04055977187946

      Documentation

      JNK Inhibitor I, (L)-Form, Cell-Permeable - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      JNK Inhibitor I, (L)-Form, Cell-Permeable - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      420116

      Références bibliographiques

      Aperçu de la référence bibliographique
      Barr, R.K., et al. 2002. J. Biol. Chem. 277, 10987.
      Bonny, C., et al. 2001. Diabetes 50, 77.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision24-July-2008 RFH
      Synonyms(L)-JNKI1, (L)-HIV-TAT₄₈₋₅₇-PP-JBD₂₀, H-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQDT-NH₂, c-Jun NH₂-terminal kinase, SAPK Inhibitor I
      DescriptionA cell-permeable, biologically active peptide consisting of a carboxyl- terminal sequence derived from the JNK-binding domain (JBD) and an amino-terminal peptide containing the HIV-TAT48-57 sequence that imparts cell-permeability. Blocks the activation domain of c-Jun NH2-terminal kinase (JNK) and prevents the activation of the transcription factor c-Jun (IC50 ~1 µM). Contains the minimal 20-amino acid inhibitory domain of islet-brain (IB), which is critical for interaction with JNK.The peptide is covalently linked to the 10-amino acid HIV-TAT48-57 sequence that acts as a carrier peptide and to two proline residue spacers. Inhibits IL-1β-induced c-Jun and c-fos expression in insulin secreting βTC-3 cells and offers protection against apoptosis. Does not affect insulin secretion and has no significant effect on the activities of ERK1, ERK2, or p38.
      FormWhite lyophilized solid
      FormulationSupplied as a trifluoroacetate salt.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₁₆₈H₂₉₃N₆₇O₄₂
      Peptide SequenceH-Gly-Arg-Lys-Lys-Arg-Agr-Gln-Arg-Arg-Arg-Pro-Pro-Arg-Pro-Lys-Arg-Pro-Thr-Thr-Leu-Asn-Leu-Phe-Pro-Gln-Val-Pro-Arg-Ser-Gln-Asp-Thr-NH₂
      Purity≥97% by HPLC
      SolubilityH₂O (2 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesBarr, R.K., et al. 2002. J. Biol. Chem. 277, 10987.
      Bonny, C., et al. 2001. Diabetes 50, 77.